A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 240 participants.

Also called NCT07394114

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 240 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07394114
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT07394114. Randomized; double masking; primary purpose treatment. Start 2026-02-24 (anticipated); primary completion 2027-08-28 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Study of HDM1005 in Participants With Type 2 Diabetes Not Controlled With Diet and Exercise Alone
Intervention (Drug)
HDM1005 1
Intervention (Drug)
HDM1005 2
Intervention (Drug)
HDM1005 injection or placebo
Lead sponsor
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. (class: industry)

Record details

Record id
cardio:ct-nct07394114
Content hash
11f79a9c2af48120c8c8bc2922c17c22eb65c99456539b9a702c035cb909f9bb